Latest Articles and Analysis

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

HHS proposed viral hepatitis quality measures for Medicaid and health equity implications.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Declining HCV infections but persistent treatment barriers and disparities remain.

Medicaid's expanding role in addressing housing instability through Section 1115 waivers.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

OIG report: 27% of Medicaid HIV enrollees lack evidence of critical services; state disparities exposed.

Medicaid unwinding: 74% of 5.5M disenrollments due to procedural errors, not ineligibility.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Mid-year policy update covering Medicaid unwinding, ACA preventive care, and public health funding.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

HCV Medicaid Access dashboard 2023 update: progress in eliminating treatment restrictions by state.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Tennessee rejects $8.3M in federal HIV prevention funding, threatening surveillance and care programs.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

2023 outlook: CVS PBM discrimination lawsuit, Medicaid enforcement, and state-sponsored discrimination threats.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.